Serum enterolactone concentrations are low in colon but not in rectal cancer patients

Anne Tuomisto1,2, Natalja P. Nørskov3, Päivi Sirniö1,2, Juha P. Väyrynen1,2,4, Shivaprakash J. Mutt2,5, Kai Klintrup6, Jyrki Mäkelä6, Knud Erik Bach Knudsen3, Markus J. Mäkinen1,2 & Karl-Heinz Herzig2,4,7

The dietary lignan metabolite, enterolactone, has been suggested to have anti-cancer functions, and high serum enterolactone concentrations have been associated with decreased risk of breast and prostate cancers. We hypothesized that serum enterolactone concentrations as a marker of plant-based foods are associated with decreased risk in colorectal cancer (CRC). We measured serum enterolactone glucuronide and sulfate concentrations by liquid chromatography-tandem mass spectrometry in 115 CRC patients and 76 sex- and age-matched controls and analyzed the results with respect to tumor parameters, clinical parameters, and systemic inflammatory markers. Patients with colon cancer had significant lower serum enterolactone glucuronide and sulfate concentrations than controls (glucuronide: median 3.14 nM vs. 6.32 nM, P < 0.001; sulfate: median 0.13 nM vs. 0.17 nM, P = 0.002), whereas rectal cancer patients had similar enterolactone levels as controls (glucuronide: median 5.39 nM vs. 6.32 nM, P = 0.357; sulfate: median 0.19 nM vs. 0.17 nM, P = 0.452). High serum enterolactone concentrations were associated with low tumor grade, high serum creatinine levels, and concomitant diabetes. In summary, our results suggest that serum enterolactone concentrations are decreased in colon but not in rectal cancer. Further investigations are required to assess whether this reflects an altered lignan metabolism by the colon microbiome.

Western diets with low fiber consumption are a risk factor for colorectal cancer (CRC)1. High-fiber, plant-based foods, such as whole grains, seeds, some vegetables and fruits, are a rich source of phytoestrogens including flavonoids and plant lignans2,3. In the colon, plant lignans are metabolized by multistep processes, catalyzed by intestinal bacteria including Moryella, Streptobacillus, Fastidiosipila and Acetanaerobacterium, resulting in the production of enterolignans, enterodiol and enterolactone.

Enterolactone has a similar structure to 17B-estradiol and is capable of binding to estrogen receptors4,5. This may explain the reported association between enterolactone and decreased risk of hormone-sensitive cancers6. Indeed, enterolactone has been reported to harbor anti-tumor activities7–9, including inhibition of tumor growth and angiogenesis, and stimulation of apoptosis10,11. Systemically, enterolignans are able to modulate the immune response by suppressing lymphocyte proliferation and cytokine production12. The cancer-protective effects of enterolactone may be facilitated by estrogen-receptor dependent and/or independent mechanisms7–9.

A recent meta-analysis of 16 studies found an inverse association between lignan intake and CRC risk, but no association between circulating enterolactone and CRC risk13. Moreover, no correlation was observed in the EPIC-Norfolk study between phytoestrogen exposure and the risk of colorectal cancer risk in an European population14, whereas another study from the same population found an association between enterolactone and CRC risk among women based on a comprehensive phytoestrogen nutrient intake database15. In addition to sex

1Cancer and Translational Medicine Research Unit, Department of Pathology, University of Oulu, Oulu, Finland. 2Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland. 3Aarhus University, Department of Animal Science, AU-Foulum, Blichers Alle 20, P.O. Box 50, DK-8830, Tjele, Denmark. 4Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 5Research Unit of Biomedicine and Biocenter of Oulu, University of Oulu, Oulu, Finland. 6Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu, Oulu, Finland; Department of Surgery, Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland. 7Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland. Correspondence and requests for materials should be addressed to A.T. (email: anne.tuomisto@oulu.fi) or K.-H.H. (email: karl-heinz.herzig@oulu.fi)
differences, tumor localization-specific differences have been reported in the association between enterolactone and CRC risk\textsuperscript{16,17}. However, despite its potential tumor-inhibiting effects, the alterations in preoperative serum enterolactone levels in CRC patients and their clinical significance have not been well-defined.

In this study, we analyzed serum enterolactone levels in 115 CRC patients in relation to the levels in 76 healthy controls, as well as tumor and patient characteristics, including systemic inflammatory markers.

**Results**

**Serum enterolactone concentrations in CRC patients and healthy controls.** Enterolactone glucuronide was the main circulating form in both CRC patients (96% of all enterolactone) and their age- and gender-matched controls (95% of all enterolactone), while sulfated enterolactone was the minor conjugation form (Table 1). The patients had significantly lower serum enterolactone glucuronide levels compared to controls (median 3.41 nM vs. 6.31 nM, respectively; \( P = 0.001 \)) and showed a tendency toward lower enterolactone sulfate levels relative to controls (median 3.41 nM vs. 6.31 nM, \( p = 0.053 \)). A strong correlation existed between enterolactone glucuronide and sulfate concentrations both in CRC patients (\( r = 0.877, P < 0.001 \)) and in control subjects (\( r = 0.796, P < 0.001 \)).

**Relationships between serum enterolactone concentrations and clinicopathological parameters.** Next, we analyzed the relationships between serum enterolactone concentrations and tumor and patient characteristics (Table 2). Low serum abundance of both the glucuronide and sulfate conjugated forms were associated with tumor localization, namely colon compared to the rectum (\( P = 0.049 \) and \( P = 0.012 \), respectively). Indeed, patients with rectal cancer (\( n = 38 \)) had similar enterolactone concentrations to controls (glucuronide: median 5.39 nM vs. 6.32 nM, \( P = 0.357 \); sulfate: median 0.19 nM vs. 0.17 nM, \( P = 0.452 \), Table 2), whereas the patients with colon cancer (\( n = 77 \)) had significantly lower concentrations of both enterolactone forms compared to control subjects (glucuronide: median 2.61 nM vs. 6.32 nM, \( P < 0.001 \); sulfate: median 0.13 nM vs. 0.17 nM, \( P = 0.002 \), Table 2). In addition, tumor differentiation was associated with serum enterolactone levels: the CRC patients with low-grade tumors had higher enterolactone levels than the patients with poorly differentiated tumors (glucuronide: \( P = 0.032 \), sulfate: \( P = 0.011 \), Table 2). Serum enterolactone levels were not associated with patient age, gender, or body mass index (BMI), tumor stage, tumor necrosis, or the the fraction of tumor cells positive for proliferation marker Ki-67 (Tables 2 and 3).

**Serum enterolactone concentrations in CRC patients with concomitant diseases.** We further assessed the effect of the concomitant diseases on serum enterolactone levels in CRC patients (Table 2). Hypertension- or cholesterol-lowering medication was not associated with altered serum enterolactone levels. Interestingly, patients with diabetes had higher enterolactone glucuronide and sulfate concentrations than the patients without diabetes (Glucuronide: \( P = 0.028 \) and sulfate: \( P = 0.021 \), Table 2). Previously, increased serum

|                     | CRC patients (\( n = 115 \)) | Healthy controls (\( n = 76 \)) |
|---------------------|-------------------------------|---------------------------------|
| **Age, mean (SD)**  | 67.63 (11.26)                 | 67.07 (10.42)                   |
| **Gender**          |                               |                                 |
| Male                | 57 (49.6%)                    | 38 (50.0%)                      |
| Female              | 58 (50.4%)                    | 38 (50.0%)                      |
| **Tumor location**  |                               |                                 |
| Proximal colon      | 49 (42.6%)                    |                                 |
| Distal colon        | 28 (24.3%)                    |                                 |
| Rectum              | 38 (33.0%)                    |                                 |
| **WHO grade**       |                               |                                 |
| Grade 1             | 14 (12.3%)                    |                                 |
| Grade 2             | 86 (74.8%)                    |                                 |
| Grade 3             | 14 (12.3%)                    |                                 |
| **TNM stage**       |                               |                                 |
| Stage I             | 17 (14.9%)                    |                                 |
| Stage II            | 46 (40.4%)                    |                                 |
| Stage III           | 30 (26.3%)                    |                                 |
| Stage IV            | 21 (18.3%)                    |                                 |
| **Body mass index (BMI), median (IQR)\textsuperscript{a}** | 26.4 (23.3–28.8) | 27.2 (24.5–30.3) |
| **Body mass index (BMI) in patients and controls aged >65, median (IQR)\textsuperscript{b}** | 26.3 (23.3–28.2) | 27.2 (24.5–30.3) |
| Enterolactone glucuronide (nM), median (IQR)\textsuperscript{c} | 3.410 (1.01–7.31) | 6.310 (2.91–10.71) |
| Enterolactone sulfate (nM), median (IQR)\textsuperscript{d} | 0.148 (0.062–0.254) | 0.168 (0.109–0.348) |

Table 1. Characteristics of the CRC patients and controls. \( ^{a} \)Data not available for controls aged less than 65 years. \( ^{b} \)CRC patients vs. healthy controls; \( P = 0.078 \). \( ^{c} P = 0.001 \). \( ^{d} P = 0.053 \). The \( P \) value are for Mann-Whitney test. Abbreviations: CRC: colorectal cancer; IQR, interquartile range; SD: standard deviation.
| Age           | Enterolactone glucuronide (nM), median (IQR) | P value | Enterolactone sulfate (nM), median (IQR) | P value |
|---------------|---------------------------------------------|---------|------------------------------------------|---------|
| < 65 years (n = 43) | 2.61 (0.80–7.18)                          | 0.217   | 0.119 (0.063–0.249)                      | 0.376   |
| ≥ 65 years (n = 72)  | 4.14 (1.10–7.37)                           |         | 0.170 (0.054–0.343)                      |         |
| Gender         |                                             |         |                                          |         |
| Male (n = 57)  | 3.64 (1.30–11.61)                          | 0.074   | 0.170 (0.072–0.392)                      | 0.163   |
| Female (n = 58) | 3.10 (0.67–6.54)                           |         | 0.132 (0.042–0.230)                      |         |
| BMI            |                                             |         |                                          |         |
| <25 (n = 47)   | 4.93 (1.34–9.33)                           | 0.285   | 0.151 (0.051–0.299)                      | 0.439   |
| 25–30 (n = 44) | 3.26 (0.65–7.08)                           |         | 0.121 (0.055–0.227)                      |         |
| >30 (n = 22)   | 3.10 (1.15–6.43)                           |         | 0.186 (0.063–0.412)                      |         |
| Time of operation |                                         |         |                                          |         |
| Winter (Dec–Feb) (n = 20) | 3.40 (0.51–6.44)                        | 0.066   | 0.148 (0.051–0.190)                      | 0.068   |
| Spring (Mar–May) (n = 34) | 3.23 (0.93–7.07)                        |         | 0.145 (0.057–0.310)                      |         |
| Summer (Jun–Aug) (n = 40) | 6.13 (2.01–11.19)                      |         | 0.213 (0.107–0.438)                      |         |
| Autumn (Sep–Nov) (n = 21) | 1.93 (0.58–3.47)                         |         | 0.081 (0.021–0.217)                      |         |
| Tumor location |                                             |         |                                          |         |
| Proximal colon (n = 49) | 2.36 (0.54–6.93)                         | 0.049   | 0.106 (0.025–0.229)                      | 0.012   |
| Distal colon (n = 28)  | 3.09 (0.81–6.38)                          |         | 0.150 (0.067–0.250)                      |         |
| Rectum (n = 38) | 5.39 (1.94–11.29)                          |         | 0.190 (0.105–0.443)                      |         |
| TNM Stage       |                                             |         |                                          |         |
| Stage I (n = 17) | 3.06 (0.62–10.32)                         | 0.846   | 0.167 (0.038–0.287)                      | 0.575   |
| Stage II (n = 46) | 3.40 (0.98–7.74)                         |         | 0.147 (0.074–0.234)                      |         |
| Stage III (n = 30) | 3.10 (1.45–9.73)                         |         | 0.170 (0.077–0.379)                      |         |
| Stage IV (n = 21) | 4.36 (0.90–5.57)                         |         | 0.115 (0.032–0.243)                      |         |
| Depth of invasion |                                         |         |                                          |         |
| T1 (n = 4)    | 0.64 (0.13–9.39)                           | 0.515   | 0.035 (0.007–0.197)                      | 0.165   |
| T2 (n = 18)   | 4.77 (1.05–10.76)                          |         | 0.179 (0.127–0.359)                      |         |
| T3 (n = 83)   | 3.39 (1.08–6.96)                           |         | 0.145 (0.063–0.299)                      |         |
| T4 (n = 9)    | 3.65 (0.90–8.14)                           |         | 0.090 (0.020–0.308)                      |         |
| Nodal metastasis |                                         |         |                                          |         |
| N0 (n = 67)  | 3.14 (0.76–7.87)                           | 0.739   | 0.148 (0.051–0.254)                      | 0.296   |
| N1 (n = 27)   | 3.61 (1.51–6.58)                           |         | 0.183 (0.108–0.301)                      |         |
| N2 (n = 19)   | 3.52 (0.80–9.33)                           |         | 0.106 (0.022–0.249)                      |         |
| Distant metastasis |                                         |         |                                          |         |
| M0 (n = 98)  | 3.59 (1.02–8.93)                           | 0.582   | 0.157 (0.063–0.286)                      | 0.271   |
| M1 (n = 31)   | 4.36 (0.90–6.57)                           |         | 0.115 (0.032–0.243)                      |         |
| WHO Grade 1–3 |                                             |         |                                          |         |
| Grade 1 (n = 14) | 3.61 (0.48–12.98)                        | 0.097   | 0.121 (0.039–0.323)                      | 0.023   |
| Grade 2 (n = 27) | 4.31 (1.50–7.45)                         |         | 0.170 (0.089–0.300)                      |         |
| Grade 3 (n = 13) | 1.51 (0.50–3.68)                         |         | 0.053 (0.012–0.192)                      |         |
| WHO Grade 1–2/3 |                                         |         |                                          |         |
| Grade 1–2 (n = 100) | 3.95 (1.10–8.00)                      | 0.032   | 0.169 (0.081–0.292)                      | 0.011   |
| Grade 3 (n = 14) | 1.51 (0.50–3.68)                         |         | 0.053 (0.012–0.192)                      |         |
| Tumor necrosis |                                             |         |                                          |         |
| 9% or less (n = 57) | 3.14 (0.72–7.35)                         | 0.557   | 0.170 (0.063–0.343)                      | 0.442   |
| 10% or more (n = 57) | 3.65 (1.19–7.83)                        |         | 0.132 (0.065–0.252)                      |         |
| Modified Glasgow Prognostic score (mGPS) | |         |                                          |         |
| 0 (n = 89)    | 3.77 (1.04–8.93)                           | 0.115   | 0.157 (0.081–0.300)                      | 0.088   |
| 1-2 (n = 26)  | 2.33 (0.78–6.18)                           |         | 0.077 (0.012–0.230)                      |         |
| Diabetes      |                                             |         |                                          |         |
| No (n = 90)   | 2.94 (0.74–6.62)                           | 0.028   | 0.132 (0.046–0.247)                      | 0.021   |
| Yes (n = 25)  | 6.45 (1.97–13.83)                          |         | 0.231 (0.094–0.553)                      |         |
| Antihypertensive medication |                                         |         |                                          |         |
| No (n = 52)  | 3.65 (1.16–7.88)                           | 0.835   | 0.130 (0.065–0.238)                      | 0.617   |
| Yes (n = 63)  | 3.14 (0.98–7.18)                           |         | 0.145 (0.051–0.384)                      |         |
| Cholesterol-lowering medication |                                         |         |                                          |         |
| No (n = 75)  | 2.73 (0.69–6.53)                           | 0.097   | 0.130 (0.051–0.246)                      | 0.094   |
| Yes (n = 40)  | 4.66 (1.07–10.49)                          |         | 0.190 (0.081–0.417)                      |         |

**Table 2.** Serum enterolactone glucuronide and enterolactone sulfate levels in relation to clinical and pathological characteristics of tumors. Abbreviations: IQR: interquartile range; BMI: body mass index. P values are for Mann-Whitney or Kruskal-Wallis test.
enterolactone concentrations have been shown in patients with diabetic renal disease\textsuperscript{18}. Therefore, we assessed the relationship between serum levels of enterolactone and kidney function marker creatinine among CRC patients. We found a significant positive correlation between enterolactone glucuronide and creatinine ($r = 0.200$, $P = 0.042$, Table 3) and a tendency towards positive correlation between enterolactone sulfate and creatinine ($r = 0.177$, $P = 0.077$, Table 3).

### Serum enterolactone concentrations in relation to systemic inflammation markers and tumor cell proliferation

The concentrations of several circulating biomarkers and tumor prognostic parameters have been reported to be related to the systemic inflammatory response in CRC patients\textsuperscript{19–24}. Therefore, we assessed, whether serum enterolactone levels were associated with systemic inflammatory markers. We measured serum concentrations of 13 cytokines (IL-1ra, IL-4, IL-6, IL-7, IL-8, IL-9, IL-12, IFNY, CXL10, CCL2, CCL4, CCL11 and PDGF-BB) and C-reactive protein. However, we did not find any statistically significant associations between serum enterolactone and these inflammatory markers (Table 3; some data not shown).

### Survival analysis

We performed a 120-month survival analysis in CRC patients (Fig. 1). The receiver operating characteristic (ROC) analysis indicated that serum enterolactone levels did not significantly discriminate survivors from non-survivors (glucuronide: cancer specific survival (CSS), area under the curve: 0.552, 95% confidence interval (CI): 0.443–0.661; sulfate: CSS, area under the curve: 0.500, 95% CI: 0.390–0.610). Univariate analysis utilizing medians as cut-off points showed that serum enterolactone levels had no statistically significant association with CSS (glucuronide: hazard ratio (HR): 1.83, 95% CI: 0.942–3.561, $P = 0.075$ and sulfate: HR: 0.96, 95% CI: 0.502–1.823, $P = 0.892$) or overall survival (glucuronide: HR: 1.71, 95% CI: 0.986–2.968, $P = 0.056$ and sulfate: HR: 1.05, 95% CI: 0.611–1.796, $P = 0.865$). In multivariate survival models, enterolactone glucuronide or enterolactone sulfate levels had no statistically significant association with CSS or overall survival (OS) (Table 4).

### Discussion

Dietary lignan derived enterolactone has been reported to possess anti-cancer activities and to be associated with lower risk of prostate cancer and breast cancer. Our main finding is that colon but not rectal cancer patients have lower serum enterolactone concentrations than healthy controls. In CRC patients, low tumor grade, increased serum creatinine levels indicating impaired renal function, and concomitant diabetes were significantly associated with higher serum enterolactone concentrations. Enterolactone is metabolized from diet-derived lignans in a multistep process catalyzed by intestinal bacteria. For example, secoisolariciresinol diglucoside, which is a lignan found in high concentration in flaxseed, is converted to enterolactone in four sequential reactions catalyzed by phylogenetically and functionally distantly related anaerobic bacteria\textsuperscript{25}. Accordingly, high urinary excretion of enterolactone has been associated with a high diversity of the gut microbial community\textsuperscript{26}. In addition, low serum enterolactone levels have been associated with low fecal total bacteria and Lactobacillus-Enterococcus counts\textsuperscript{27}. Thus, we hypothesize that low serum enterolactone concentrations in colon cancer patients may reflect paucity of lignan-converting bacteria in these patients, or an intracolonic environment sub-optimal to bacterial metabolism and lignan conversion. Accordingly, CRC have been linked to gut microbiota dysbiosis\textsuperscript{28} and antibiotics are known to reduce circulating enterolactone levels\textsuperscript{29,30}. Unfortunately, we do not have data on the frequency of antibiotics usage in our cohort subjects.

Earlier studies have reported that enterolactone exerts anti-proliferative activities on prostate and breast cancer in vivo\textsuperscript{31,32}. However, in our CRC patient cohort, serum enterolactone abundance was not associated with tumor cell proliferation, as assessed by Ki-67 immunohistochemistry (Table 3). We further hypothesized that serum enterolactone could be altered by the presence of a systemic inflammatory response to the tumor. However, we detected no association with different cytokines or CRP. Furthermore, serum enterolactone levels were not associated with tumor stage. Currently, the prognostic classification of CRC is mainly based on tumor stage, while additional prognostic parameters could help to target the tumor with more individualized treatments\textsuperscript{33,34}. Given the reported anti-tumor effects of enterolactone, we hypothesized that high serum enterolactone could be associated with improved patient outcome. Our cohort had a 10-year survival follow-up but no significant associations were detected between serum enterolactone levels and patient survival.

We measured serum enterolactone as glucuronide and sulfate conjugates. Consistent with earlier studies in healthy subjects\textsuperscript{34,35} we found that glucuronide conjugate was the major circulating enterolactone metabolite in both CRC patients and controls. Enterolactone, as well as other polyphenols, are readily metabolized from diet-derived lignans in a multistep process catalyzed by intestinal bacteria.

### Survival analysis

**Table 3.** Correlations between serum enterolactone levels and systemic inflammatory markers CRP and IL6, tumor cell proliferation marker Ki-67, and kidney function marker creatinine. \textsuperscript{a}Numbers indicate Pearson correlation coefficients ($r$) for logarithmically transformed variables.

| Correlation          | Serum C-reactive protein | Serum IL-6 | Ki-67 tumor cell percentage | Serum creatinine |
|----------------------|--------------------------|------------|-----------------------------|-----------------|
| Entero lactone       | Pearson r                | $P$ value  | Pearson r                   | $P$ value       |
| Glucuronide Enterolactone | $-0.044$                | 0.654      | $-0.081$                    | 0.412           |
| Sulfate Enterolactone | $-0.146$                | 0.135      | $-0.171$                    | 0.084           |

| Correlation          | Serum C-reactive protein | Serum IL-6 | Ki-67 tumor cell percentage | Serum creatinine |
|----------------------|--------------------------|------------|-----------------------------|-----------------|
| Entero lactone       | Pearson r                | $P$ value  | Pearson r                   | $P$ value       |
| Glucuronide Enterolactone | $0.177$                | 0.068      | $0.015$                     | 0.880           |
| Sulfate Enterolactone | $0.200$                 | 0.042      | $0.177$                     | 0.077           |
conjugated in the intestinal wall and in the liver. Glucuronidation and sulfation are detoxification mechanisms to eliminate potentially harmful effects of enterolactone. Tumor targeted glucuronic acid cleavage from the enterolactone-glucuronide in the tumor tissue is currently under investigation as a potential adjuvant therapy in prostate cancer.

We found that CRC patients with diabetes had increased serum enterolactone levels. A previous study found elevated serum enterolactone levels in patients with diabetic nephropathy and a strong correlation between serum enterolactone and creatinine levels. Accordingly, our results support the positive correlation between serum enterolactone glucuronide and creatine, suggesting that decreased urinary secretion of enterolactone may contribute to the increased serum enterolactone levels in a subset of CRC patients.

Earlier reported determinants of serum enterolactone concentrations include consumption of lignan-containing foods, constipation, smoking and BMI. Especially, lignan-containing plant foods such as grains, fruits and vegetables are enriched with the dietary fiber, phytoestrogen, and unsaturated fatty acids. Increased dietary intake of lignans or fortification of food with the plant lignans have resulted in increased serum enterolactone levels. In the Nordic population, a healthy diet includes apples and berries, roots and cabbage, rye, oats, barley, low-fat milk products, rapeseed oil, and fish. However, in our CRC cohort detailed food intake questionnaires were not available. Nevertheless, we did not detect statistically significant association between serum enterolactone levels and the BMI of CRC patients.

Our CRC cohort was cross sectional study with a long follow-up period from a single province in Northern Finland (65° latitude). The study was limited by its sample size, comprising 115 CRC patients and 76 healthy controls. Due to cross-sectional study design, we were not able to assess, whether enterolactone reduced the risk for colon cancer and/or affected colon cancer progression at early stages. Therefore, additional studies are required to further clarify the significance of the decreased serum enterolactone levels in colon cancer patients.

In conclusion, we found significantly decreased levels of enterolactone in colon cancer, but not in rectal cancer patients. Since a diverse gut microbiota plays a crucial role for an efficient conversion of plant to enterolignans, microbiome homeostasis may be disturbed in patients with colon, but not with rectal cancer, which requires further investigation. Serum enterolactone levels were not significantly associated with patient gender or age, tumor stage, systemic inflammatory markers, and survival.

Figure 1. Kaplan-Meier curves showing the relationships between enterolactone glucuronides (A, B) and sulfate (C, D) in cancer specific survival (A and C, and overall survival (B, D)).
was calculated from serum CRP and albumin values. Four of the 149 (3.4%) cases were not applicable to this analysis due to the possible confounding effects to the local tumor characteristics. Four of the 149 (3.4%) cases were not applicable to this study due to insufficient sample material. Clinical data was collected from the clinical records and a questionnaire. The 10 year follow-up data was acquired from the clinical records and Statistics Finland. Age and sex matched control serum samples were acquired from healthy voluntary blood donors (Finnish Red Cross, Oulu, Finland; n = 50, age < 65 years), patient’s relatives, and cataract surgery patients (Oulu University Hospital; n = 50, age ≥ 65 years).

The study was accepted by the Ethical Committee of the Oulu University Hospital (42/2005, 122/2009) and performed according to the National Guidelines and the principles of the Declaration of Helsinki. All the patients and controls signed an informed consent to participate in the study.

Histopathological analysis. The tumors were staged according to TNM and graded according to the WHO 2010 criteria. The percentage of tumor tissue showing coagulative necrosis was evaluated by inspecting all the available hematoxylin and eosin stained tumor sections. Tumor necrosis was specified as an area with increased eosinophilia and nuclear shrinkage, fragmentation and disappearance. The proliferation index, denoting the percentage of Ki-67 positive tumor cells in the hotspots, was determined as described earlier.

Analysis of blood samples. Preoperative serum samples were collected in tubes without clot activator. The samples were centrifuged and stored at −70 °C until the analysis. Serum inflammatory markers were analyzed with Bio-Plex Pro Human pre-manufactured 27-Plex Cytokine Panel (Bio-Rad, Hercules, CA, USA). A total of 13 of 27 (48.1%) cytokines (IL-1ra, IL-4, IL-6, IL-7, IL-8, IL-9, IL-12, IFNγ, CXL10, CCL2, CCL4, CCL11 and PDGF-BB) had three or fewer values outside the assay working range and were included in the study. Serum CRP levels and serum albumin levels were measured in the laboratory of Oulu University Hospital and mgPS was calculated from serum CRP and albumin values. Serum creatinine levels were analyzed with nuclear magnetic resonance metabolomics platform, equipped with Bruker AVANCE III 500 MHz and Bruker AVANCE III 600 MHz spectrometers (Bruker, Billerica, MA, USA).

Enterolactone measurements. Serum enterolactone concentrations were quantified using a novel high-throughput liquid chromatography–mass spectrometry (LC-MS)/MS method by measuring the free enterolactone or intact form of either glucuronide or sulphate conjugated enterolactone, as previously described. The method was validated according to the guidelines of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency. Internal standards and their stability was tested previously. Intraplate accuracy, precision and recovery of enterolactone were tested at low, medium and high concentrations and the relative standard deviation did not exceed 15%. Briefly, standard curves and test serum sample were prepared using standards of (±)-enterolactone-mono-β-D-glucuronide and (±)-enterolactone monosulfate ammonium salt from ReseaChem (Burgdorf, Switzerland) and enterolactone from Plantech (Berkshire, UK). Serum samples were cleaned in solid phase extraction (SPE) hydrophilic/lipophilic balanced (HBL) 96-well plates from Waters (Torrance, CA, USA) and eluted with 50/40/10% acetonitrile (ASC)/methanol (MeOH)/H2O and internal standard (Glycine-1 13C) was added to the eluate. The LC-MS/MS measurements were performed on a microLC 200 series from Eksigent/AB Sciex (Redwood City, CA, USA) and Q Trap 500 mass spectrometer from AB Sciex equipped with an ESI source. The microLC was equipped with a phenyl column from Eksigent/AB Sciex (Redwood City, CA, USA). The data were analysed using the Analyst software 1.6 from AB Sciex (Framingham, MA, USA).

Statistical analyses. Statistical analyses were performed using IBM SPSS Statistics for Windows version 22.0 (IBM Corporation, Armonk, NY, USA). Normally distributed continuous variables are presented as mean (standard deviation, SD), whereas other continuous variables are presented as median (interquartile range, IQR). Correlations between two continuous variables were presented as Pearson correlation coefficients (r). Statistical significances of the differences in serum enterolactone levels between the different study groups and categorical variables were analyzed by Mann-Whitney U test or Kruskal-Wallis test. ROC analysis was used to evaluate the capacity of the serum enterolactone level to discriminate survivors from non-survivors. Cox regression models were used in the survival analyses. In all the tests P < 0.05 was considered statistically significant.

| CSS | OS |
|-----|----|
| **Age (<65 vs. ≥65)** | 2.47 | 1.12–5.47 | 0.025 | 2.35 | 1.22–4.54 | 0.011 |
| **Tumor invasion (T1–T2 vs. T3–T4)** | 0.68 | 0.21–2.16 | 0.510 | 0.90 | 0.38–2.12 | 0.801 |
| **Nodal metastases (N0 vs. N1–N2)** | 6.56 | 2.65–16.25 | 4.7E-5 | 2.52 | 1.35–4.68 | 0.004 |
| **Distant metastases (M0 vs. M1)** | 7.79 | 3.15–19.25 | 9.0E-6 | 4.73 | 2.31–9.67 | 2.1E-5 |
| **Serum enterolactone glucuronide (≤3.410 nM vs. >3.410 nM)** | 1.18 | 0.44–3.18 | 0.750 | 1.50 | 0.69–3.26 | 0.303 |
| **Serum enterolactone sulfate (≤0.148 nM vs. >0.148 nM)** | 0.71 | 0.30–1.69 | 0.439 | 0.75 | 0.37–1.55 | 0.443 |

Table 4. Multivariate analysis of 120-month cancer-specific survival (CSS) and overall survival (OS) of CRC patients. Abbreviations: CI: confidence interval; HR: hazard ratio.
References

1. Park, Y. et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. *JAMA* **294**, 2849–2857 (2005).

2. Horner, N. K. et al. Dietary determinants of plasma enterolactone. *Cancer Epidemiol. Biomarkers Prev.* **11**, 121–126 (2002).

3. Stumpf, K., Pietinen, P., Puska, P. & Adlercreutz, H. Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland. *Cancer Epidemiol. Biomarkers Prev.* **9**, 1369–1372 (2000).

4. Mueller, S. O., Simon, S., Chae, K., Metzler, M. & Korach, K. S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. *Toxicol. Sci.* **80**, 14–25 (2004).

5. Penttinen, P. et al. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. *Endocrinology* **148**, 4875–4886 (2007).

6. Adolphe, J. L., Whiting, S. J., Juurlink, B. H., Thorpe, L. U. & Alcorn, J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. *Br. J. Nutr.* **103**, 929–938 (2010).

7. Hullah, M. A. et al. Enterolignan-producing phenotypes are associated with increased gut microbial diversity and altered composition in premenopausal women in the United States. *Cancer Epidemiol. Biomarkers Prev.* **24**, 546–554 (2015).

8. Qu, H., Madi, R. L., Takemoto, D. J., Baybutt, R. C. & Wang, W. Lignans are involved in the antitumor activity of wheat bran in colon cancer SW480 cells. *J. Nutr.* **135**, 598–602 (2005).

9. Ayella, A. et al. Cytostatic inhibition of cancer cell growth by lignan secoisolariciresinol diglucoside. *Nutr. Res.* **30**, 762–769 (2010).

10. Thompson, L. U., Chen, J. M., Li, T., Strasser-Weippl, K. & Goss, P. E. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. *Clin. Cancer Res.* **11**, 3828–3835 (2005).

11. Saarinen, N. M. et al. Dietary larisiresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. *Int. J. Cancer* **123**, 1196–1204 (2008).

12. Corsini, E. et al. Enterodiol and enterolactone modulate the immune response by acting on nuclear factor-kappaB (NF-kappaB) signaling. *J. Agric. Food Chem.* **58**, 6678–6684 (2010).

13. Jiang, R., Botma, A., Rudolph, A., Husing, A. & Chang-Claude, J. Phyto-oestrogens and colorectal cancer risk: a systematic review and dose-response meta-analysis of observational studies. *Br. J. Nutr.* **116**, 2115–2128 (2016).

14. Ward, H. et al. Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. *Cancer Epidemiol. Biomarkers Prev.* **17**, 2891–2894 (2008).

15. Ward, H. A. et al. Breast, colorectal, and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an improved database. *Am. J. Clin. Nutr.* **91**, 440–448 (2010).

16. Ko, K. P. et al. Plasma phytoestrogens concentration and risk of colorectal cancer in two different Asian populations. *Clin. Nutr.* **37**, 1675–1682 (2018).

17. Johnsen, N. F. et al. Plasma enterolactone and risk of colon and rectal cancer in a case-cohort study of Danish men and women. *Cancer Causes Control* **21**, 153–160 (2010).

18. von Hertzen, L. et al. Highly elevated serum phyto-oestrogen concentrations in patients with diabetic nephropathy. *J. Intern. Med.* **255**, 602–609 (2004).

19. Sirnö, P. et al. Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer. *Sci. Rep.* **7**, 5374 (2017).

20. Väyrynen, J. P. et al. Decreased preoperative serum 25-Hydroxyvitamin D levels in colorectal cancer are associated with systemic inflammation and serrated morphology. *Sci. Rep.* **6**, 36519 (2016).

21. Väyrynen, J. P. et al. Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival. *Sci. Rep.* **8**, 1126 (2018).

22. McSorley, S. T. et al. Normocytic anaemia is associated with systemic inflammation and poorer survival in patients with colorectal cancer treated with curative intent. *Int. J. Colorectal Dis.* **34**, 401–408 (2019).

23. Sirnö, P. et al. High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer. *Br. J. Cancer* **119**, 213–219 (2018).

24. Sirnö, P. et al. Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival. *Br. J. Cancer* **120**, 238–246 (2019).

25. Clavel, T., Dore, J. & Blaut, M. Bioavailability of lignans in human subjects. *Nutr. Res. Rev.* **19**, 187–196 (2006).

26. Holma, R. et al. Low serum enterolactone concentration is associated with low colonic Lactobacillus-Enterococcus counts in men but is not affected by a symbiotic mixture in a randomised, placebo-controlled, double-blind, cross-over intervention study. *Br. J. Nutr.* **111**, 301–309 (2014).

27. Sohba, I. et al. Microbial dysbiosis in colorectal cancer (CRC) patients. *PLoS One* **27**, e16393 (2011).

28. Kuijsten, A., Arts, I. C., Hollman, P. C. van't Veer, P. & Kampman, E. Plasma enterolignans are associated with lower colorectal adenoma risk. *Cancer Epidemiol. Biomarkers Prev.* **15**, 1132–1136 (2006).

29. Bolvig, A. K. et al. Effect of Antibiotics and Diet on Enterolactone Concentration and Metabolome Studied by Targeted and Nontargeted LC–MS Metabolomics. *J. Proteome Res.* **16**, 2135–2150 (2017).

30. Azrad, M. et al. Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. *J. Med. Food* **16**, 357–360 (2013).

31. Bergman Jungestrom, M., Thompson, L. U. & Dabrosin, C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. *Clin. Cancer Res.* **13**, 1061–1067 (2007).

32. Schmoll, H. J. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. *Ann. Oncol.* **23**, 2479–516 (2012).

33. Glynn-Jones, R. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **28**, iv22–iv40 (2017).

34. Norkov, N. P., Krya, C., Olsen, A., Tjonneland, A. & Knudsen, K. E. High-Throughput LC–MS/MS Method for Direct Quantification of Glucuronidated, Sulfated, and Free Enterolactone in Human Plasma. *J. Proteome Res.* **15**, 1051–1058 (2016).

35. Adlercreutz, H. et al. Lignan and isoflavonoid conjugates in human urine. *J. Steroid Biochem. Mol. Biol.* **52**, 97–103 (1995).

36. Jansen, G. H. et al. Uptake and metabolism of enterolactone and enterodiol by human colon epithelial cells. *Arch. Biochem. Biophys.* **435**, 74–82 (2005).

37. Dean, B., Chang, S., Doss, G. A., King, C. & Thomas, P. E. Glucuronidation, oxidative metabolism, and bioactivation of enterolactone in rhesus monkeys. *Arch. Biochem. Biophys.* **429**, 244–251 (2004).

38. Lindsay, J., Wang, L. L., Li, Y. & Zhou, S. F. Structure, function and polymorphism of human cytosolic sulfotransferases. *Curr. Drug Metab.* **9**, 99–105 (2008).

39. Di, Y., Ji, S., Wolf, P., Krol, E. S. & Alcorn, J. Enterolactone glucuronide and beta-glucuronidase in antibody directed enzyme prodrug therapy for targeted prostate cancer cell treatment. *AAPS Pharm. Sci. Tech.* **18**, 2336–2345 (2017).
40. Kilkkinen, A. et al. Determinants of serum enterolactone concentration. *Am. J. Clin. Nutr.* 73, 1094–1100 (2001).
41. Vanharanta, M. et al. Phloem fortification in rye bread elevates serum enterolactone level. *Eur. J. Clin. Nutr.* 56, 952–957 (2002).
42. Perala, M.-M. et al. A healthy Nordic diet and physical performance in old age: findings from the longitudinal Helsinki Birth Cohort Study. *Br. J. Nutr.* 115, 878–886 (2016).
43. Juntunen, K. S. et al. Consumption of wholemeal rye bread increases serum concentrations and urinary excretion of enterolactone compared with consumption of white wheat bread in healthy Finnish men and women. *Br. J. Nutr.* 84, 839–846 (2000).
44. Kantola, T. et al. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. *Br. J. Cancer* 107, 1729–36 (2012).
45. Nagtegaal, I. D. et al. Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer. *J. Pathol.* 197, 20–7 (2002).
46. Kantola, T. et al. Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers. *Br. J. Cancer* 111, 1605–1613 (2014).
47. Moilanen, J. M. et al. Collagen XVII expression correlates with the invasion and metastasis of colorectal cancer. *Hum. Pathol.* 46, 434–442 (2015).
48. Sobin, L. H. & Wittekind, C. *TNM classification of malignant tumours.* (Wiley-Liss, 2002).
49. Hamilton, S. R. et al. Carcinoma of the colon and rectum. In: Bosman F, Carneiro F, Hruban R, Theise N, eds *WHO classification of tumours of the digestive system.* Lyon, IARC Press 134–46 (2010).
50. Väyrynen, S. A. et al. Clinical impact and network of determinants of tumour necrosis in colorectal cancer. *Br. J. Cancer* 114, 1334–1342 (2016).
51. Väyrynen, J. P. et al. The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer. *Int. J. Cancer* 139, 112–21 (2016).
52. Soininen, P., Kangas, A. J., Würzt, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ. Cardiovasc. Genet.* 8, 192–206 (2015).
53. Nørskov, N. P. et al. Targeted LC-MS/MS Method for the Quantitation of Plant Lignans and Enterolignans in Biofluids from Humans and Pigs. *J. Agric. Food Chem.* 63, 6283–92 (2015).

Acknowledgements
We thank Ms. Riitta Vuento for her expert assistance in the preparation of the study material. This work was supported by grants from Medical Research Center Oulu and Thelma Mäkikyrö Foundation.

Author Contributions
Study conception and design: K.H. Herzig, M.J. Mäkinen. Enterolactone measurements: N.P. Nørskov, K.E. Bach Knudsen, S.J. Mutt. Data collection: P. Sirniö, J.P. Väyrynen, K. Klintrup, J. Mäkelä, M.J. Mäkinen, A. Tuomisto. Statistical analysis: A. Tuomisto, P. Sirniö, J.P. Väyrynen. Manuscript draft: A. Tuomisto, P. Sirniö, J.P. Väyrynen. The manuscript was reviewed and edited by all authors.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019